Medpace, Inc. is a global contract research organization (CRO) that provides comprehensive drug and device development services to pharmaceutical, biotechnology and medical device companies. Founded in 1992 by Dr. August J. Troendle and headquartered in Cincinnati, Ohio, Medpace has grown from a small regional operation into one of the industry’s leading full-service CROs. The company operates under the leadership of Dr. Troendle, who serves as Chairman and CEO, and a senior management team with extensive experience in clinical research, regulatory affairs, and global project management.
Medpace offers end-to-end clinical development solutions spanning all phases of clinical trials, from early-stage Phase I studies through post-marketing surveillance. Its core services include protocol design, site selection and management, patient recruitment, data management, biostatistics, and regulatory consulting. The company’s in-house central laboratory and bioanalytical services support complex trial requirements, while its medical imaging division provides specialized analysis for oncology, cardiology and neurology studies. Medpace’s integrated approach is designed to streamline project timelines and enhance data quality for sponsors pursuing new drug and device approvals.
With operations in more than 40 countries, Medpace serves clients across North America, Europe, Asia-Pacific and Latin America. The company’s global footprint encompasses full-service offices, regional clinical trial sites and specialized laboratories, enabling efficient coordination of multi-center studies. Medpace’s therapeutic expertise covers oncology, cardiovascular and metabolic diseases, infectious diseases, immunology, neurology and vaccines, positioning the organization to support a wide range of clinical research programs. Its cross-functional teams work collaboratively to address regulatory requirements in major markets, including the United States, European Union and Asia.
Over its three decades of operation, Medpace has maintained a focus on scientific rigor, operational excellence and patient safety. The company’s quality management system and adherence to industry regulations, such as Good Clinical Practice (GCP) guidelines, ensure consistent trial conduct and reliable data generation. By partnering with emerging and established sponsors, Medpace continues to advance medical innovation and facilitate the development of new therapies worldwide.
AI Generated. May Contain Errors.
Free MEDP Stock Alerts